{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:20:54Z","timestamp":1791980454493,"version":"4.4.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.37120","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T20:57:22Z","timestamp":1613163442000},"page":"e2037120","source":"Crossref","is-referenced-by-count":158,"title":["Association of Performance Status With Survival in Patients With Advanced Non\u2013Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy"],"prefix":"10.1001","volume":"4","author":[{"given":"Kartik","family":"Sehgal","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu R.","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page","family":"Widick","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poorva","family":"Bindal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle C.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Shea","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Rangachari","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Costa","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"issue":"22","key":"zoi201107r1","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1200\/JCO.18.02118","article-title":"Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence.","volume":"37","author":"Passaro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi201107r2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research.","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"9","key":"zoi201107r3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S2213-2600(20)30107-7","article-title":"Immunotherapy in lung cancer: effective for patients with poor performance status?","volume":"8","author":"Alessi","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"19","key":"zoi201107r4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201107r5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1053\/j.seminoncol.2018.08.007","article-title":"FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies.","volume":"45","author":"Marur","year":"2018","journal-title":"Semin Oncol"},{"issue":"11","key":"zoi201107r6","doi-asserted-by":"publisher","first-page":"e1355","DOI":"10.1200\/OP.20.00010","article-title":"Adoption of immune checkpoint inhibitors and patterns of care at the end of life.","volume":"16","author":"Riaz","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"10","key":"zoi201107r7","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1002\/cncr.32782","article-title":"Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.","volume":"126","author":"Petrillo","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"zoi201107r8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","article-title":"Chemotherapy use, performance status, and quality of life at the end of life.","volume":"1","author":"Prigerson","year":"2015","journal-title":"JAMA Oncol"},{"issue":"20","key":"zoi201107r9","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"zoi201107r10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/sj.bjc.6602836","article-title":"A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson\u2019s index.","volume":"93","author":"Colinet","year":"2005","journal-title":"Br J Cancer"},{"issue":"5","key":"zoi201107r11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.21037\/tlcr","article-title":"Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?","volume":"8","author":"Piper","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"zoi201107r12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s40425-018-0447-2","article-title":"Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies.","volume":"6","author":"Soyano","year":"2018","journal-title":"J Immunother Cancer"},{"key":"zoi201107r13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2020.05.028","article-title":"Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small-cell lung cancer.","author":"Sehgal","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"zoi201107r14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2020.02.023","article-title":"First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.","volume":"130","author":"Facchinetti","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi201107r15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001007","article-title":"Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status.","volume":"8","author":"Alessi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"9","key":"zoi201107r16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1080\/0284186X.2020.1781249","article-title":"Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab.","volume":"59","author":"Friedlaender","year":"2020","journal-title":"Acta Oncol"},{"issue":"9","key":"zoi201107r17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"9","key":"zoi201107r18","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153).","volume":"14","author":"Spigel","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"23","key":"zoi201107r19","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1200\/JCO.2013.50.1502","article-title":"Patients with advanced non-small-cell lung cancer and marginal performance status: walking the tight rope towards improved survival.","volume":"31","author":"West","year":"2013","journal-title":"J Clin Oncol"},{"issue":"25","key":"zoi201107r20","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1200\/JCO.20.00721","article-title":"Performance status in cancer: not broken, but time for an upgrade?","volume":"38","author":"Scott","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2776172\/sehgal_2021_oi_201107_1612371664.78093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T20:57:25Z","timestamp":1613163445000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2776172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37120","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}